Advertisement

Topics

Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of ...

10:00 EDT 23 Aug 2017 | BioMedReports - Blog

"We are encouraged by the performance of SB-061 in the clinic thus far," said Nathan Bachtell, M.D., Chief Medical Officer of Symic Bio. "By

Read more...

Original Article: Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of ...

NEXT ARTICLE

More From BioPortfolio on "Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of ..."

Advertisement
Quick Search
Advertisement
Advertisement